FDA Approves First Direct RAS Inhibitor, Doubling Survival in Pancreatic Cancer and Cracking Oncology’s ‘Undruggable’ Target

The Food and Drug Administration on Wednesday approved Rasonque (daraxonrasib), a once-daily pill from Revolution Medicines that directly inhibits multiple forms of the RAS protein — the mutation driving tumor growth in more than 90% of pancreatic cancers and roughly a quarter of all human cancers. For patients with metastatic pancreatic adenocarcinoma who have exhausted one prior therapy or cannot tolerate combination chemotherapy, the approval marks the first time a treatment targeting the root molecular driver of their disease has reached the clinic.

In the pivotal trial, patients receiving Rasonque lived a median of 13.2 months compared with 6.7 months on standard chemotherapy, a 60% reduction in the risk of death. Disease progression was delayed, and deterioration in pain and quality of life occurred later. The drug does not require biomarker testing to identify a specific RAS variant before prescribing.

The decision arrived 6.5 months ahead of the FDA’s user-fee deadline, accelerated by a new review framework allowing international regulators to evaluate oncology applications alongside the agency. “This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, director of the FDA’s Oncology Center of Excellence. The application was also reviewed under the National Priority Voucher pilot program and carried Breakthrough Therapy and Orphan Drug designations.

RAS proteins have been pursued as cancer targets for four decades. Their smooth, featureless surface lacked the deep pockets that traditional small molecules typically bind, earning the target a reputation as “undruggable.” Revolution Medicines developed a covalent inhibitor that binds to a conserved cysteine residue exposed when RAS cycles through its active state, effectively trapping the protein in an inactive conformation. The approach inhibits multiple RAS isoforms — KRAS G12D, G12V, G12R, G13D, and others — rather than a single mutation.

“This gives physicians the confidence that directly inhibiting RAS can make a striking difference for patients,” said Brian Wolpin, the trial’s principal investigator and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. Anna Berkenblit of the Pancreatic Cancer Action Network called it “the most significant advance we have seen in the fight against pancreatic cancer.”

Pancreatic cancer remains the third-leading cause of cancer death in the United States, with an estimated 67,530 new diagnoses and 52,740 deaths projected for 2026. The five-year survival rate has stalled at 13% for three years, compared with 70% across all cancers combined. Roughly 80% of patients are diagnosed after the disease has metastasized, where five-year survival hovers near 3%.

The approval’s implications extend beyond pancreatic cancer. KRAS mutations drive approximately 30% of non-small cell lung cancers, 40% of colorectal cancers, and a significant share of ovarian and other malignancies. Revolution Medicines is already advancing daraxonrasib through late-stage lung cancer trials, and the drug’s pan-RAS mechanism suggests potential utility across multiple tumor types. Oncologists anticipate substantial off-label use while those trials mature.

Revolution Medicines set a list price of $39,800 for a 30-day supply. A patient support program allows eligible insured patients to pay as little as $0 out of pocket, and an expanded access program launched in May has already treated more than 2,000 patients.

The breakthrough also reshapes the landscape for combination strategies. RAS inhibitors act on intracellular signaling pathways, while emerging mRNA cancer vaccines target surface antigens. Researchers believe pairing the two approaches — attacking the cell from inside and out — could yield durable responses across previously intractable cancers.